key: cord-0858795-nwifmuu2
authors: Khezri, Mohammad Rafi; Zolbanin, Naime Majidi; Ghasemnejad-berenji, Morteza; Jafari, Reza
title: Azithromycin: Immunomodulatory and Antiviral Properties for SARS-CoV-2 Infection
date: 2021-05-17
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2021.174191
sha: 4fcfaa8f21329a3cc3d0a864a4a7a286b367b15a
doc_id: 858795
cord_uid: nwifmuu2

Azithromycin, a member of the macrolide family of antibiotics, is commonly used to treat respiratory bacterial infections. Nevertheless, multiple pharmacological effects of the drug have been revealed in several investigations. Conceivably, the immunomodulatory properties of azithromycin are among its critical features, leading to its application in treating inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, azithromycin may directly inhibit viral load as well as its replication, or it could demonstrate indirect inhibitory impacts that might be associated with the expression of antiviral genes. Currently, coronavirus disease 2019 (COVID-19) is an extra urgent issue affecting the entire world, and it is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS), which is associated with hyper inflammation due to cytokine release, is among the leading causes of death in COVID-19 patients with critical conditions. The present paper aims to review the immunomodulatory and antiviral properties of azithromycin as well as its potential clinical applications in the management of COVID-19 patients.

. Additionally, the Ang II-angiotensin AT 1 receptor axis causes the formation of a soluble form of IL-6 receptor α (sIL-6Rα) by mediating ADAM17 (Eguchi et al., 2018) . The binding of IL-6 to sIL-6Rα contributes to signal transducer and activator of transcription 3 (STAT3) activation in non-immune cells. Furthermore, full activation of NF-ҡB requires STAT3 (Murakami et al., 2019) . Eventually, the production of VEGF, MCP-1, IL-6, and IL-8 occurs by activation of STAT3 and NF-ҡB through the IL-6 amplifier (Murakami et al., 2019) . On the other hand, IL-6 induces energy-dependent neutrophil extracellular traps (NETs) formation (Joshi et al., 2013) . NETs are capable of promoting fibrosis (Chrysanthopoulou et al., 2014) and lung damage (Lefrançais et al., 2018) detected in lung samples of COVID-19 patients (Radermecker et al., 2020 , Middleton et al., 2020 . The other inducer of NET formation is myeloperoxidase (MPO), which can be complexed with DNA and is rising in patients (Radermecker et al., 2020) . NET formation capability is a feature of activated neutrophils and increased neutrophil recruitment to the lungs, which may lead to autoinflammation reactions (Barnes et al., 2020 , Chen et al., 2020 . Additionally, neutrophils may contribute to the stress oxidative, shown in patients with COVID-19, and leads to tissue damage (Abouhashem et al., 2020 , Laforge et al., 2020 . Lymphocytopenia is an imperative clinical indicator of SARS-CoV-2 severity (Tan et al., 2020) which might be caused by infection of lymphocytes and recruitment of lymphocytes to the lung tissue (Wang et al., other activator of NF-ҡB is extracellular signal-regulated kinase 1/2 (ERK1/2) (Shim et al., 2011) , which is also suppressed by azithromycin (Blau et al., 2007) . Simultaneous inhibition of PI3K/AKT/NF-ҡB and ERK1/2/NF-ҡB by azithromycin contributes to the suppression of proinflammatory cytokines production (Wang et al., 2018 , Blau et al., 2007 . The other transcription factors involved in the inflammation induction are activator protein 1 (AP-1) and STAT proteins (Schonthaler et al., 2011) . These factors are activated by molecules such as TNF-α (Desai et al., 2012 , Rahman et al., 2002 , Guo et al., 1998 , Miscia et al., 2002 . Thereby, azithromycin can inhibit the inflammation induced through STATs and AP-1 by two mechanisms: the reduction of the TNF-α levels (Blasi et al., 2010) and the direct inhibition of STATs and AP-1 activation (Haydar et al., 2019 , Bosnar et al., 2011 . Additionally, the accumulation of azithromycin in inflammatory cells, especially macrophages and neutrophils, have been demonstrated in different studies (Gladue et al., 1989 , Wildfeuer et al., 1989 , Wildfeuer et al., 1996 . Azithromycin reduces the expression of adhesion molecules such as intercellular adhesion molecule (ICAM) (Cigana et al., 2006) and vascular cell adhesion protein (VCAM) ( Bartold et al., 2013) , leading to neutrophil recruitment suppression (Tsai et al., 2004) . It has been revealed that the ICAM and VCAM expression is controlled by the PI3K/AKT signaling pathway (Tsoyi et al., 2010 , Lin et al., 2019 . Consequently, the inhibitory effects of azithromycin on ICAM and VCAM molecules may be associated with inhibition of the PI3K/AKT signaling pathway. Regarding the impact of azithromycin on the formation of NETs, it has been indicated that pre-treatment with the drug reduces the release of NETs (Bystrzycka et al., 2017) . The so-called effect might be associated with lowering the MPO activity proved in several studies (Culic et al., 2005 , Legssyer et al., 2006 . The expression of GM-CSF, which has been indicated to regulate neutrophils activity and its high expression in lung injuries, is augmented by TNF-α through PI3K/AKT signaling J o u r n a l P r e -p r o o f pathway . Thus, the reduction of the GM-CSF expression by azithromycin may be linked to its effect on suppressing TNF-α expression (Ivetić Tkalcević et al., 2006) and PI3K/AKT signaling pathway. On the other hand, GM-CSF stimulates PI3K/AKT signaling pathway to induce its effect (Qiu et al., 2014) . The other factor involved in inflammatory respiratory diseases (e.g., asthma) is a ligand for chemokine receptor CXCR3 called IP-10 that is expressed in epithelial/T cells and required chemotaxis of Th1 cells (Cole et al., 1998) . It has been indicated that azithromycin suppresses the expression of IP-10 through NF-ҡB/p65 and mitogen-activated protein kinase (MAPK)-Jun N-terminal kinases (JNKs)/ERK pathways (Kuo et al., 2019) . In addition to the stated arguments, azithromycin enhances the phagocytosis of neutrophils or epithelial cells by alveolar macrophages (Hodge et al., 2006) . Fig. 1 represents the role of azithromycin in controlling the immune system.

There is no adequate evidence concerning the effect of azithromycin on the viral load in various infections. Although it has generally been demonstrated that azithromycin holds antiviral properties, the actual mechanism is not distinctly understood. Even though Azithromycin might inhibit viral replication, the majority of studies accentuate boosting the immune system to fight against the virus rather than relying on Azithromycin. In a study by Beigelman et al., it has been observed that azithromycin reduces the inflammatory mediators after induction of viral bronchoalveolar infection in mice. Additionally, it has been indicated that azithromycin attenuates post-viral weight loss and reduces total leukocyte accumulation (Beigelman et al.,

Furthermore, it has been reported that azithromycin induces the expression of antiviral genes such as IFNs and IFN-stimulated genes, including oligoadenylate synthase, melanoma J o u r n a l P r e -p r o o f differentiation-associated gene 5, a retinoic acid-inducible gene I, MxA, and viperin. Besides, it has been shown that azithromycin reduces the replication and release of rhinoviruses in bronchial epithelial cells (Gielen et al., 2010 , Menzel et al., 2016 . Zika virus is the next virus on which the effect of azithromycin has been studied in terms of virus replication. In the study by Bosseboeuf et al., the impact of azithromycin was investigated on Zika virus-infected Vero cells, and it was indicated that azithromycin inhibits the Zika virus replication in Vero cells (Bosseboeuf et al., 2018) . Moreover, in another study, Retallack et al. have demonstrated that azithromycin reduces the proliferation of the Zika virus and its cytopathic effects (Retallack et al., 2016) . Furthermore, it has been reported that pre-treatment with azithromycin has the same results against the Ebola virus (Kouznetsova et al., 2014 , Du et al., 2020 , Madrid et al., 2015 and Dengue (Li et al., 2019) . One of the most thought-provoking studies regarding the antiviral potential of azithromycin is the study on influenza A(H1N1) pdm09 virus infection. In the study by Tran et al., it has been demonstrated that although azithromycin validates no effect on the attachment of the virus to the cell surface, it suppresses virus entry into the host cell during the early phase of infection. Moreover, the effects of this drug were shown to be independent of anti-influenza conventional medicines (Tran et al., 2019) .

Regardless of the immunomodulatory role of azithromycin, its direct antiviral effects are also an important issue. In this regard, ACE2 and TMPRSS2 are the extra attractive goals. Concerning the ACE2, its downregulation leads to inflammation induction (Shi et al., 2013) . There are two types of ACE2: the first type is attached to the membrane, and the other is the soluble form (Batlle et al., 2020) . Based on the in silico studies, it has been estimated that azithromycin can target the binding interaction point between ACE2 and spike protein of the SARS-CoV-2 (Braz J o u r n a l P r e -p r o o f et al., 2020). As described earlier, the downregulation of ACE2 by the virus leads to increased Ang II levels. On the other hand, it has been demonstrated that Ang II induces the PI3K/AKT signaling pathway through the angiotensin AT 1 receptor and eventually contributes to the inflammatory pathway (Zhang et al., 2016 , Zhao et al., 2014 . Thus, it can be concluded that azithromycin could suppress Ang II-induced inflammation through inhibition of the PI3K/AKT signaling pathway. Activation of the angiotensin AT 1 receptor by Ang II contributes to the upregulation of the ADAM17 expression leading to cleavage of the membrane-anchored ACE2 and changing to an active soluble form (Xu et al., 2017) . It has been shown that overexpression of ACE2 enhances the entry of SARS-CoV to the host cells in a mouse model (Yang et al., 2007) . It seems that the overexpression of membrane-anchored ACE2 leads to an increase of the virus entry to the cells, and the soluble form of ACE2 decreases viral entrance. It has been indicated that human recombinant soluble ACE2 inhibits SARS-CoV infection by two mechanisms: a) by neutralizing the virus without endocytosis b) by suppressing inflammation induced by the virus (Monteil et al., 2020 , Xue et al., 2014 . However, differences in the amino acid sequence of the ACE and ACE2 cause ACE inhibitors to have no effect on the COVID-19 treatment (Crackower et al., 2002) . Concerning the TMPRSS2 as the other therapeutic target, its expression is engaged with the PI3K/AKT signaling pathway (Mishra and Dey, 2021). The expression of TMPRSS2 is upregulated by androgen receptors due to several androgen receptor elements located on the promoter of the TMPRSS2 gene, and it can be a reason for higher sensitivity of men to COVID-19 (Shen et al., 2017 , Wambier et al., 2020 . On the other hand, it has been demonstrated that IL-6 inhibits androgen receptors transactivation through the PI3K/AKT signaling pathway (Yang et al., 2003) , and the activation of androgen receptors by androgens leads to PI3K/AKT signaling pathway activation (Sun et al., 2003) . Therefore, as a J o u r n a l P r e -p r o o f target for azithromycin, although activation of this pathway may be a mechanism for TMPRSS2 expression, further research is required to approve the so-called notion. Additionally, it has been indicated that azithromycin suppresses the pathways involved in the TMPRSS2 expression Additionally, it has been represented that the activation of the PI3K/AKT signaling pathway is required for bovine ephemeral fever virus entry to the host cells by enhancing the clathrinmediated virus endocytosis (Cheng et al., 2015) . The involvement of this pathway in the entry of transmissible gastroenteritis virus, which demands clathrin for its endocytosis, has been shown in another study (Hu et al., 2018) . Based on the aforementioned findings, the suppression of the PI3K/AKT signaling pathway by azithromycin may inhibit SARS-CoV-2 entry to the host cells through clathrin-dependent endocytosis.

After all, the effect of azithromycin on SARS-CoV-2 replication has been evaluated in a study by Touret et al. In this study, which was accomplished in Vero cells, pre-treatment with 2.12 µM of azithromycin as EC50 inhibited the replication of the virus (Touret et al., 2020) . Although the exact mechanism of this inhibition is not evidently cognized, according to a hypothesis, it may be related to the pH of the lysosome, which is required for the shedding of the viral genetic. It is proposed that an acidic environment may be required for uncoating of coronaviruses similar to J o u r n a l P r e -p r o o f the other enveloped viruses such as HIV and influenza (Greber et al., 1994) . Because of the weak base feature of azithromycin, it can be declared that azithromycin upsurges the pH level and disrupts acidic conditions, which are compulsory for the uncoating process (Damle et al., 2020) .

The effects of azithromycin on the other SARS-CoV-2 receptor, CD147, are not fittingly scrutinized; however, there exist several hypotheses. The effect of azithromycin on reducing the MMPs' expression related to CD147 formulates the hypothesis that azithromycin may inhibit CD147, and eventually, virus entry to the host cells (Ulrich and Pillat, 2020) . Inhibition of Plasmodium falciparum invasion by azithromycin in different cases makes the idea extra potent (Wilson et al., 2015) . On the other hand, it has been demonstrated that CD147 induces the PI3K/AKT signaling pathway activation, contributing to NF-ҡB induction and pro-inflammatory cytokines production (Chen et al., 2009 , Fang et al., 2015 . In addition to inflammation, PI3K/AKT signaling pathway is involved in the fibrosis induction in different organs (Zang et al., 2019 , Qiu et al., 2019 . Over-activation of this pathway by SARS-CoV-2 through CD147 and angiotensin AT 1 receptor may be the major cause of fibrosis in COVID-19 patients. In addition, once the expression of TMPRSS2 is regulated by PI3K/AKT signaling pathway, its overexpression by the virus may lead to an increase in the TMPRSS2 expression and eventually more virus entry to the cells. Fig. 2 represents the mechanisms of SARS-CoV-2 entry to the host cells, its pathogenicity, and possible mechanisms of azithromycin to suppress these processes.

Most clinical studies on the effects of azithromycin on the COVID-19 treatment have been conducted in combination with hydroxychloroquine. The first clinical study to inspect the effects of azithromycin in the treatment of COVID-19 was done in Marseilles, France. In this study, patients were divided into three groups: hydroxychloroquine received group, hydroxychloroquine + azithromycin-treated group, and a group consisting of the patients with no 18.1% in the entire cohort. The mortality rates were 13.5% in the hydroxychloroquine alone group, 22.4% among those receiving azithromycin alone, 20.1% among the hydroxychloroquine + azithromycin group and 26.4% for neither drugs. Thus, it can be deduced that treatment with azithromycin is associated with a significant reduction of COVID-19-related mortality (Arshad et al., 2020) . In addition to the so-called studies, Albani and et al. (Albani et al., 2020) evaluated the impact of azithromycin on hospital mortality in COVID-19 patients alone or combined with hydroxychloroquine. In this study, 1430 patients with COVID-19 were admitted to the hospital, and the outcome was available for 1376 of them. A group of 587 patients received azithromycin, and the other group with 377 patients was treated with hydroxychloroquine alone or combined with azithromycin. According to the results of this study, treatment of COVID-19 patients with azithromycin was associated with lower in-hospital mortality, and hydroxychloroquine was not associated with reduced or increased mortality. A retrospective cohort study, including 377 patients hospitalized for pneumonia caused by COVID-19 treatment with hydroxychloroquine combined with azithromycin, reduced the mortality rate compared to no treatment (Lauriola et al., 2020) . Interestingly, in this study, treatment with hydroxychloroquine alone was not associated with lower mortality rate and days of in-hospital remaining, whereas in combination with azithromycin was inversely associated. Conversely, several studies discussed the adverse effects of azithromycin and hydroxychloroquine combination or the antiviral power of the drugs.

In a pre-proof study, it has been indicated that the combination treatment of azithromycin and hydroxychloroquine has no evidence of clinical benefit and strong antiviral activity in severe patients (Molina et al., 2020) . Besides, Furtado et al. (Furtado et al., 2020) with 183 patients as the control group. It was shown that in severe COVID-19, patients treated with azithromycin did not improve clinical outcomes. In response to this study, it can be referred to another study that examined the effect of azithromycin on patients with COVID-19 at the onset of early symptoms. This study included 1061 patients treated with azithromycin combined with hydroxychloroquine prior to the occurrence of COVID-19 complications demonstrated a low mortality rate and decent clinical outcome in patients (Million et al., 2020) . Based on the results of other studies, QT interval prolongation, which is the widely acknowledged adverse effect of hydroxychloroquine, is increased once hydroxychloroquine is combined with azithromycin for COVID-19 treatment (Chorin et al., 2020a , Chorin et al., 2020b , Maraj et al., 2020 .

Although various studies have been conducted to gauge the effect of azithromycin on COVID-19, the majority of these studies have examined its adjuvant impact along with hydroxychloroquine. There is a lack of adequate information concerning the combination of azithromycin with the other drugs employed for COVID-19 treatment. Due to the effect of azithromycin on the suppression of the SARS-CoV-2-induced inflammation and its replication in human cells, it can be utilized in combination with other medications such as corticosteroids, antiviral agents, and antibodies. In addition, since azithromycin affects the transcription of numerous factors, its usage in the early stages of the disease might play a crucial role in its efficacy. However, it requires further investigation in order to prove the consistency of the results. mechanisms of azithromycin to suppress these processes. SARS-CoV-2 binds to ACE2 and causes its downregulation on the cell surface. Eventually, the levels of Ang II increases leading to PI3K/AKT signaling pathway activation by mediating angiotensin AT 1 receptor and inducing the expression of the pro-inflammatory cytokines such as IL-6. First, azithromycin prevents the binding of the virus spike to ACE2 because of its more affinity with the ACE2, secondly, azithromycin inhibits PI3K/AKT signaling pathway activation and suppresses Ang II-induced inflammation and fibrosis. On the other hand, the other SARS-CoV-2 receptor, CD147, activates the PI3K/AKT signaling pathway that contributes to inducing the expression of the proinflammatory cytokines. Thus, azithromycin suppresses CD147-dependent inflammation through this pathway. The effect of azithromycin on the expression of the TMPRSS2 and CD147 and its

Epidermal growth factor receptor is a cofactor for transmissible gastroenteritis virus entry

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice

Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating with severe COVID-19 infection

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines

WHO Director-General's opening remarks at the media briefing on COVID-19-11

Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J TMPRSS2 and TMPRSS11D Required by SARS-CoV-2

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction

Targeting inflammation by modulating the Jun/AP-1 pathway

EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall

Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion

TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections

SUN, metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages

Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study

Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process

Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection

PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3β/GATA-6 signaling pathways in TNFα-activated human endothelial cells

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Androgen sensitivity gateway to COVID-19 disease severity

CD147 induces angiogenesis through a vascular endothelial growth factor and hypoxia-inducible transcription factor 1α-mediated pathway in rheumatoid arthritis

Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K/Akt signaling pathway

Inflammation suppression by dexamethasone via inhibition of CD147-mediated NF-κB pathway in collagen-induced arthritis rats

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes

Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions

Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum

Clinical Relevance and Role of Neuronal AT(1) Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension

CD147 Aggravated Inflammatory Bowel Disease by Triggering NF-κB-Mediated Pyroptosis

Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis

Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells

Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Angiotensin-(1-7) abrogates angiotensin II-induced proliferation, migration and inflammation in VSMCs through inactivation of ROS-mediated PI3K/Akt and MAPK/ERK signaling pathways

Azithromycin influences airway remodeling in asthma via the PI3K/Akt/MTOR/HIF-1α/VEGF pathway

Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Pathogenic T cells and inflammatory monocytes incite inflammatory